Neoadjuvant Botensilimab/Balstilimab Combo Induces Early Eff

Neoadjuvant botensilimab/balstilimab led to robust responses in both patients with resectable mismatch repair–proficient and –deficient colorectal cancer.

Related Keywords

Boston , Massachusetts , United States , Newyork Presbyterian Hospital , New York , Mexico , American , Mexican , Daiichi Sankyo Astrazeneca , Guardant Health , Agenus Inc , Astrazeneca , Rarecyte Inc , Foundation Medicine , Pashtoon Murtaza Kasi , Weill Cornell Medicine , African American , Southeast Asian , Middle Eastern , Precision Biosensors , Elicio Therapeutics , Delcath Systems , Exact Sciences , Neogenomics Laboratories , Taiho Oncology , Taiho Pharmaceutical , Advanced Accelerator Applications , Boston Scientific , Neoadjuvant Botensilimab Balstilimab , Resectable Mismatch Repair Proficient Colorectal Cancer , Mismatch Repair Deficient Colorectal Cancer , Nct05571293 , Nest 1 Trial , D , Us ,